Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study.

Abstract

In phase one of the REALIZE study, zolmitriptan nasal spray demonstrated a significant headache response from 10 min post-dose and total symptom relief from 30 min post-dose. The objective of phase two was to investigate patients' dosing patterns, satisfaction and preference following open-label treatment with the nasal spray. Up to 3 attacks were treated. The ITT population consisted of 851 patients. The median time from onset of symptoms to treatment was 1 h 15 min (primary endpoint). Most patients reported being satisfied or very satisfied with zolmitriptan nasal spray (75.7%). Furthermore, the majority of patients would be willing to use zolmitriptan nasal spray in the future (59.8%) and preferred zolmitriptan nasal spray over previous therapies (57.8%). Zolmitriptan nasal spray was well tolerated. Most patients were satisfied with zolmitriptan nasal spray, were willing to continue using it and preferred it to previous therapies.

• Authors: Marek Gawel, Jürgen Aschoff, Arne May, Bruce R Charlesworth, REALIZE Study Group
• Journal: The journal of headache and pain (J Headache Pain) Vol. 6 Issue 5 Pg. 405-11 (Oct 2005) ISSN: 1129-2369 [Print] England
• PMID: 16362714 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Oxazolidinones
• Serotonin Receptor Agonists
• Tryptamines
• zolmitriptan

Topics

• Adolescent
• Adult
• Dose-Response Relationship, Drug
• Drug Administration Routes
• Female
• Humans
• Male
• Middle Aged
• Migraine Disorders (drug therapy, physiopathology)
• Nasal Cavity (drug effects)
• Oxazolidinones (administration & dosage, adverse effects)
• Pain Measurement (drug effects)
• Patient Satisfaction
• Serotonin Receptor Agonists (administration & dosage, adverse effects)
• Time Factors
• Treatment Outcome
• Tryptamines (administration & dosage, adverse effects)